J&J to buy Cougar for $1 billion

Johnson & Johnson is to buy oncology specialist Cougar Biotechnology for $1 billion in cash to boost its pipeline of late-stage cancer therapeutics.

Johnson & Johnson is to buy oncology specialist Cougar Biotechnology for $1 billion in cash to boost its pipeline of late-stage cancer therapeutics.

The move will allow J&J to expand into cancer targets where it is currently absent, such as prostate cancer. Cougar's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category